You are here: Home » Companies » News
Business Standard

Natco gets USFDA nod for anti-sleep tablets

Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015

Sharath Chowdary  |  Hyderabad 

Sun Pharma extends savings card program for cancer drug in US

Hyderabad-based drug firm has received final approval from the US Food and Drug Administration (USFDA) for a generic version of tablets used as a wakefulness promoting agent for oral administration.

The has approved the Abbreviated New Drug Application (ANDA) for tablets, 50 mg, 150 mg and 250 mg.

Natco and its marketing partner plan to launch this product in the US market immediately.

is used to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and It is commonly used off-label to treat attention deficit hyperactivity disorder, chronic fatigue syndrome, and major depressive disorder. It has been shown to improve vigilance in air traffic controllers.

US-based Cephalon, a subsidiary of Teva Pharmaceuticals, sells 50 mg, 150 mg and 250 mg tablets under brand name Nuvugil in the US market. Nuvugil had sales of around $480 million during the year 2015, according to IMS Health data.

RECOMMENDED FOR YOU

Natco gets USFDA nod for anti-sleep tablets

Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015

Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015 Hyderabad-based drug firm has received final approval from the US Food and Drug Administration (USFDA) for a generic version of tablets used as a wakefulness promoting agent for oral administration.

The has approved the Abbreviated New Drug Application (ANDA) for tablets, 50 mg, 150 mg and 250 mg.

Natco and its marketing partner plan to launch this product in the US market immediately.

is used to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and It is commonly used off-label to treat attention deficit hyperactivity disorder, chronic fatigue syndrome, and major depressive disorder. It has been shown to improve vigilance in air traffic controllers.

US-based Cephalon, a subsidiary of Teva Pharmaceuticals, sells 50 mg, 150 mg and 250 mg tablets under brand name Nuvugil in the US market. Nuvugil had sales of around $480 million during the year 2015, according to IMS Health data.

image
Business Standard
177 22

Natco gets USFDA nod for anti-sleep tablets

Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015

Hyderabad-based drug firm has received final approval from the US Food and Drug Administration (USFDA) for a generic version of tablets used as a wakefulness promoting agent for oral administration.

The has approved the Abbreviated New Drug Application (ANDA) for tablets, 50 mg, 150 mg and 250 mg.

Natco and its marketing partner plan to launch this product in the US market immediately.

is used to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy, and It is commonly used off-label to treat attention deficit hyperactivity disorder, chronic fatigue syndrome, and major depressive disorder. It has been shown to improve vigilance in air traffic controllers.

US-based Cephalon, a subsidiary of Teva Pharmaceuticals, sells 50 mg, 150 mg and 250 mg tablets under brand name Nuvugil in the US market. Nuvugil had sales of around $480 million during the year 2015, according to IMS Health data.

image
Business Standard
177 22